Adults who take growth hormone (GH) replacement for GH deficiency have an improved quality of life (QoL) sustained for up to 10 years, according to an observational study of patients enrolled in the Hypopituitary Control and Complications Study (HypoCSS).
The QoL of patients with GH deficiency has been found to be poorer on average than that of the general population. But data have shown that patients’ QoL improved after 6 to 8 months of GH, with results suggesting these improvements were sustained for up to 4 years.
Researchers wanted to build upon this previous evidence and investigate whether this improvement could last up to 10 years. They collected data from 1,532 total patients, with 1,436 patients having adult-onset GH deficiency and 96 having childhood-onset GH deficiency.
To measure the patients’ QoL, the researchers used the Questions on Life Satisfaction–Hypopituitarism (QLS-H), a questionnaire developed specifically to measure QoL in adults with GH deficiency. The QLS-H has been validated in seven countries. Each patient in this analysis had QLS-H data from the start of their GH treatment in addition to QLS-H data from each year after treatment for 10 years.
Both adult-onset and childhood-onset patients experienced a significant increase in their QLS-H Z-scores from the start of their GH replacement to year 1, with a mean increase of 0.77 for adult-onset patients and 0.50 for childhood-onset patients. This initial improvement remained statistically significant for all 10 years for adult-onset patients and for years 1 to 4, 6 and 7 for childhood-onset patients.
The patients who saw the most improvement in QoL were those who were not depressed, lived in Europe, had poorer Z-scores at the start of treatment, had lower BMIs and had no impaired vision.
Despite the improvement of QoL with treatment, the average QLS-H score of the GH patients remained much lower than the average of the general population.
These study results were published in the Journal of Clinical Endocrinology & Metabolism.
Previous studies have shown that growth hormone therapy can improve quality of life, which is already lower, in patients with growth hormone deficiency. This study, published in the Journal of Clinical Endocrinology & Metabolism, more thoroughly explores the effects of GH treatment in this patient population.